Amarin rises as Citi says Buy on selloff, accelerating Vascepa sales » 11:2002/1802/18/20
AMRN, RDY, HKMPF
Shares of Amarin (AMRN)…
Tesla target hikes headline today's top Wall Street calls » 10:3302/1802/18/20
TSLA, AAPL, AMRN, CTL, AEO, M
Check out today's top…
Fly Intel: Top five analyst upgrades » 10:1502/1802/18/20
AMRN, DUK, KN, BC, WWE
Catch up on today's…
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Amarin (AMRN) upgraded to Buy from Neutral at Citi with analyst Joel Beatty saying with the stock trading 27% lower since November, now is an attractive time to buy. 2. Duke Energy (DUK) upgraded to Outperform from Neutral at Credit Suisse with analyst Michael Weinstein sayin he sees last year's $2.5B equity forward that was issued to support any contingency associated with the Atlantic Coast Pipeline project as providing Duke Energy the flexibility to fund additional accretive organic growth in the meantime. 3. Knowles (KN) upgraded to Overweight from Neutral at Piper Sandler with analyst Harsh Kumar saying he expects the operational issues affecting March quarter gross margin and the demand concerns surrounding Chinese handsets to ease entering the June 2020 quarter. 4. Brunswick (BC) upgraded to Outperform from Market Perform at Raymond James with analyst Joseph Altobello saying Brunswick has emerged as the pure-play leader in the U.S. marine industry with a balanced portfolio across boats, engines and parts and accessories. 5. WWE (WWE) upgraded to Overweight from Equal Weight at Consumer Edge. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Citi upgrades Amarin to Buy from Neutral after 27% selloff since November » 06:0502/1802/18/20
Citi analyst Joel Beatty…
Citi analyst Joel Beatty upgraded Amarin to Buy from Neutral with a price target of $24, down from $27. The shares closed Friday down 7c to $17.62. With the stock trading 27% lower since November, now is an attractive time to buy, Beatty tells investors in a research note. The analyst still believes Vascepa sales will "accelerate strongly" over the next couple years. Further, Amarin will likely emerge from the ongoing intellectual property litigation with Vascepa exclusivity largely intact, contends Beatty.
Amarin upgraded to Buy from Neutral at Citi » 06:0102/1802/18/20
Citi analyst Joel Beatty…
Citi analyst Joel Beatty upgraded Amarin to Buy from Neutral with a price target of $24, down from $27.
|Over a week ago|
Amarin story has 'too many unknowns,' InvestorPlace contributor says » 10:4002/1302/13/20
Dana Blankenhorn, an…
Dana Blankenhorn, an InvestorPlace contributor, wrote in an article published by the stock-idea sharing site: "Amarin stock is filled with known unknowns...The uncertainty is why I have recommended against buying Amarin shares. That and the fact I'm not about to get it. Not everyone will benefit from this drug. You need to see persistent high triglycerides, even with statin therapy, to be a real candidate for it." Reference Link
Dr. Reddy's to acquire select business divisions of Wockhardt in India » 05:2302/1202/12/20
Dr. Reddy's Laboratories announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.1850 Crores.The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr. Reddy's along with related sales and marketing teams; and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees. The business undertaking is being transferred on a slump sale basis. The transaction is expected to be closed in the first quarter of the financial year 2020-21.
Dr. Reddy's announces launch of Trientine Hydrochloride Capsules USP in U.S. » 05:3002/0702/07/20
Dr. Reddy's announced the launch of Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine Capsules, approved by the FDA. Dr. Reddy's Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles.
Jefferies confident Amarin will win patent trial, sees up to 20% rally » 09:1801/2901/29/20
AMRN, RDY, HKMPF
Court proceedings for the…
Court proceedings for the Amarin (AMRN) versus Dr. Reddy's (RDY) and Hikma Pharmaceuticals (HKMPF) case have ended, following seven days of expert witness testimony, Jefferies analyst Michael Yee tells investors in a research note. The judge did not provide a preliminary ruling or hint at which way she is ruling, but she did state the written ruling will be made by March 31, Yee points out. With the proceedings completed, and Dr. Reddy's and Hikma having presented their best case, Yee is now more confident that Amarin is likely to prevail, "removing the chief overhang on the stock." Amarin shares have been relatively range bound the last month despite positive news on the competitive front with two key competitor trials having failed, Yee contends. He attributes this to uncertainty associated with the patent trial and the potential risk for Reddy's and Hikma, two prospective generics for Amarin's Vascepa, to present some "bombshell" evidence. However, the analyst now thinks it will be hard for the judge to not rule in favor of Amarin. Yee sees the stock up 10%-20% on a positive ruling and keeps a Buy rating on Amarin with a $30 price target. The stock closed Tuesday at $20.26.
Dr. Reddy's downgraded to Outperform from Buy at CLSA » 05:5501/2801/28/20
CLSA analyst Alok Dalal…
CLSA analyst Alok Dalal downgraded yesterday afternoon Dr. Reddy's to Outperform from Buy with a price target of INR 3,450. The company's EBITDA beat fiscal Q3 expectations but a large impairment drove a net profit miss, Dalal tells investors in a post-earnings research note. The stock's valuation "offers limited room to slip up" and already "bakes in positives," the analyst contends.